Jun 2017 $30 M No. 6 $10 to $50 million 43
Exosome Theranostics, Inc.: Raise no. 6, Jun 2017 × Investors in this round 43 investors had bought by the notice of Jul 6, 2017: 43 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $30 M of $30 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice John Boyce · Executive Officer, Director Thomas McLain · Executive Officer William Kelly · Executive Officer Geert-Jan Mulder · Director Joseph Slattery · Director Kapil Dhingra · Director Peter Johann · Director Steven Soignet · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by William Kelly, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 6, 2017. Read the notice at the SEC .
equity SEC Aug 2015 $16 M No. 5 $10 to $50 million 9
Exosome Theranostics, Inc.: Raise no. 5, Aug 2015 × Investors in this round 9 investors had bought by the notice of Sep 15, 2015: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $16 M (amount offered: indefinite)
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Thomas McLain · Executive Officer, Director · Chief Executive Officer and Director of Issuer William Kelly · Executive Officer · Chief Financial Officer and Secretary of Issuer Geert-Jan Mulder · Director Joseph Slattery · Director Kapil Dhingra · Director Peter Johann · Director Steven Soignet · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Thomas McLain, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 15, 2015. Read the notice at the SEC .
equity, options SEC Jun 2015 $1 M No. 4 Under $2 million 12
Exosome Theranostics, Inc.: Raise no. 4, Jun 2015 × Investors in this round 12 investors had bought by the notice of Jul 6, 2015: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $2 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Thomas McLain · Executive Officer, Director · Chief Executive Officer and Director of Issuer William Kelly · Executive Officer · Chief Financial Officer and Secretary of Issuer Geert-Jan Mulder · Director Joseph Boystak · Director Joseph Slattery · Director Kapil Dhingra · Director Peter Johann · Director Steven Soignet · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Thomas McLain, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 6, 2015. Read the notice at the SEC .
equity, options SEC Mar 2014 $27 M No. 3 $10 to $50 million 26
Exosome Theranostics, Inc.: Raise no. 3, Mar 2014 × Investors in this round 26 investors had bought by the notice of Mar 13, 2014: 26 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $27 M of $40 M offered; $13 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $896,992
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice James McCullough · Executive Officer, Director Sara Barrington · Executive Officer Dhingra Kapil · Director Geert-Jan Mulder · Director Joseph Boystak · Director Joseph Slattery · Director Peter Johann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Leerink Partners LLC (CRD 39011) · Boston, Massachusetts Sold in CT, IL, MA, NJ, NY Hudson Capital Advisors BD LLC (CRD 132424) · Santa Monica, California Sold in CT, NY Remarks in the notice On the amounts: “The amount sold shown Item 13 and number of investors shown in Item 14 include $13,849,959 from 5 non-US investors.”On the use of proceeds: “The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business”Signed by James McCullough, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 13, 2014. Read the notice at the SEC .
equity SEC Aug 2012 $7 M No. 2 $2 to $10 million 2
Exosome Theranostics, Inc.: Raise no. 2, Aug 2012 × Investors in this round 2 investors had bought by the notice of Aug 15, 2013: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $9 M offered; $2 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice James McCullough · Executive Officer, Director Sara Barrington · Executive Officer Dhingra Kapil · Director Geert-Jan Mulder · Director Joseph Boystak · Director Joseph Slattery · Director Peter Johann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “The Issuer will use proceeds for general working capital purposes which includes payments to its executive officers and other employees in the ordinary course of business”Signed by James McCullough, Chief Executive Officer. Source: SEC Form D and 3 amendments, newest notice filed Aug 15, 2013. Read the notice at the SEC .
debt, options SEC Apr 2010 $10 M No. 1 $2 to $10 million 10
Exosome Theranostics, Inc.: Raise no. 1, Apr 2010 × Investors in this round 10 investors had bought by the notice of May 12, 2010: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $23 M offered; $13 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Preferred Stock and Warrants
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions $270,000
Finders' fees none
Paid to its own people $1,170,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Greg Zdechlik · Executive Officer James McCullough · Executive Officer, Director Sara Barrington · Executive Officer Wayne Comper · Executive Officer Geert-Jan Mulder · Director Georg Nebgen · Director Joseph Boystak · Director Peter Johann · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Hudson Capital Advisors BD LLC (CRD 132424) · Los Angeles, California Sold in CA, IL, MA, NY Remarks in the notice On fees: “In addition to cash consideration, a warrant to purchase 17,906 shares of common stock of the company was also issued”On the amounts: “Future Investments are based on the company achieving specified milestones.”Signed by James McCullough, Chief Executive Officer. Source: SEC Form D, newest notice filed May 12, 2010. Read the notice at the SEC .
equity, options SEC